Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?Venkat Reddy, Maria Leandro, Christian Klein et al.|Lara D. Veeken|2021Cited by 38
P149 Evaluating outcomes for patients with systemic lupus erythematosus treated with obinutuzumab, a humanised anti-CD20 monoclonal antibody, following secondary non-depletion of B cells and non-response with rituximabVikram M K Joseph, Maria Leandro, Venkat Reddy et al.|Lara D. Veeken|2025Cited by 1
POS1238 EVALUATING OUTCOMES FOR PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH OBINUTUZUMAB, A HUMANISED ANTI-CD20 MONOCLONAL ANTIBODY, FOLLOWING SECONDARY NON-DEPLETION OF B CELLS AND NON-RESPONSE WITH RITUXIMABM. Leandro, Coziana Ciurtin, Venkat Reddy et al.|Annals of the Rheumatic Diseases|2025Cited by 0